Last updated: 2026-09-09 04:52:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Edgewise Therapeutics, Inc. (EWTX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $43.84, with a market capitalization of $4.68B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $13.69 to $48.40. This page covers its latest market performance, valuation, price trends and company information.
$4.68B | |
$42.85 | |
$48.40 | |
$5.12 | |
$43.07 | |
943.35K | |
1.31M | |
-- | |
$48.40 | |
$13.69 | |
-- | |
-- |
Edgewise Therapeutics, Inc. (EWTX) last closed at $43.07 as of 2026-09-08 23:31:00, unchanged from the previous close of $43.07.
During the latest regular trading session, EWTX traded between $5.12 and $48.40, with a volume of 943.35K shares. The closing price was near the upper end and near the upper end of its 52-week range.
Over the past seven days, Edgewise Therapeutics, Inc. (EWTX) moved from $44.19 to $43.84, representing a decline of 0.80% ($0.35).
The stock traded between $40.64 and $47.28 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 952.67 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 86.9%
EWTX is currently trading at $43.84, placing it 86.9% of the way from its 52-week low of $13.69 to its 52-week high of $48.40. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 127 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Edgewise Therapeutics, Inc. (EWTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.